International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy

Sjors Klompmaker; Thijs de Rooij; Bas Groot Koerkamp; Anuraj H. Shankar; Uwe Siebert; Marc G. Besselink; A. James Moser

doi:10.1097/SLA.0000000000003659

International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy

Sjors Klompmaker^*, Thijs de Rooij, Bas Groot Koerkamp, Anuraj H. Shankar, Uwe Siebert, Marc G. Besselink, A. James Moser^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Abstract

Objective: To quantify the nationwide impact of minimally invasive distal pancreatectomy (MIDP) on major morbidity as compared with open distal pancreatectomy (ODP).Background: A recent randomized controlled trial (RCT) demonstrated significant reduction in time to functional recovery after MIDP compared with ODP, but was not powered to assess potential risk reductions in major morbidity.Methods: International cohort study using the American College of Surgeons' National Quality Improvement Program (ACS-NSQIP) (88 centers; 2014-2016) to evaluate the association between surgical approach (MIDP vs ODP) and 30-day composite major morbidity (CMM; death or severe complications) with external model validation using Dutch Pancreatic Cancer Group data (17 centers; 2005-2016). Multivariable logistic regression assessed the impact of nationwide MIDP rates between 0% and 100% on postoperative CMM at conversion rates between 0% and 25%, using estimated marginal effects. A sensitivity analysis tested the impact at various scenarios and patient populations.Results: Of 2921 ACS-NSQIP patients, 1562 (53%) underwent MIDP with 18% conversion, and 1359 (47%) underwent ODP. MIDP was independently associated with reduced CMM [odds ratio (OR) 0.50, 95% confidence interval (CI) 0.42-0.60, P < 0.001], confirmed by external model validation (n = 637, P < 0.003). The association between rising MIDP implementation rates and falling postoperative morbidity was linear between 0% (all ODP) and 100% (all MIDP). The absolute risk reduction for CMM was 11% (95% CI 7.3%-15%) at observed conversion rates and improved to 14% (95% CI 11%-18%) as conversion approached 0%. Similar effects were seen across subgroups.Conclusion: This international study predicted a nationwide 11% risk reduction for CMM after MIDP versus ODP. which is likely to improve as conversion rates decrease. These findings confirm secondary outcomes of the recent LEOPARD RCT.

Original language	English
Pages (from-to)	E966-E973
Number of pages	8
Journal	Annals of Surgery
Volume	274
Issue number	6
DOIs	https://doi.org/10.1097/SLA.0000000000003659
Publication status	Published - Dec 2021

Bibliographical note

Funding Information:
Funding: This project was funded by non-profit partners: The Netherland-America-Foundation Fulbright Scholarship Program, the Alliance of Families Fighting Pancreatic Cancer, the Greg & Cathy Griffith Family Foundation, the John F. Fortney Foundation.

Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/SLA.0000000000003659Licence: Unspecified

Cite this

@article{dafa9903d17e4affb79764441eda22fa,

title = "International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy",

abstract = "Objective: To quantify the nationwide impact of minimally invasive distal pancreatectomy (MIDP) on major morbidity as compared with open distal pancreatectomy (ODP).Background: A recent randomized controlled trial (RCT) demonstrated significant reduction in time to functional recovery after MIDP compared with ODP, but was not powered to assess potential risk reductions in major morbidity.Methods: International cohort study using the American College of Surgeons' National Quality Improvement Program (ACS-NSQIP) (88 centers; 2014-2016) to evaluate the association between surgical approach (MIDP vs ODP) and 30-day composite major morbidity (CMM; death or severe complications) with external model validation using Dutch Pancreatic Cancer Group data (17 centers; 2005-2016). Multivariable logistic regression assessed the impact of nationwide MIDP rates between 0% and 100% on postoperative CMM at conversion rates between 0% and 25%, using estimated marginal effects. A sensitivity analysis tested the impact at various scenarios and patient populations.Results: Of 2921 ACS-NSQIP patients, 1562 (53%) underwent MIDP with 18% conversion, and 1359 (47%) underwent ODP. MIDP was independently associated with reduced CMM [odds ratio (OR) 0.50, 95% confidence interval (CI) 0.42-0.60, P < 0.001], confirmed by external model validation (n = 637, P < 0.003). The association between rising MIDP implementation rates and falling postoperative morbidity was linear between 0% (all ODP) and 100% (all MIDP). The absolute risk reduction for CMM was 11% (95% CI 7.3%-15%) at observed conversion rates and improved to 14% (95% CI 11%-18%) as conversion approached 0%. Similar effects were seen across subgroups.Conclusion: This international study predicted a nationwide 11% risk reduction for CMM after MIDP versus ODP. which is likely to improve as conversion rates decrease. These findings confirm secondary outcomes of the recent LEOPARD RCT.",

author = "Sjors Klompmaker and {de Rooij}, Thijs and Koerkamp, {Bas Groot} and Shankar, {Anuraj H.} and Uwe Siebert and Besselink, {Marc G.} and Moser, {A. James}",

note = "Funding Information: Funding: This project was funded by non-profit partners: The Netherland-America-Foundation Fulbright Scholarship Program, the Alliance of Families Fighting Pancreatic Cancer, the Greg & Cathy Griffith Family Foundation, the John F. Fortney Foundation. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",

year = "2021",

month = dec,

doi = "10.1097/SLA.0000000000003659",

language = "English",

volume = "274",

pages = "E966--E973",

journal = "Annals of Surgery",

issn = "0003-4932",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

TY - JOUR

T1 - International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy

AU - Klompmaker, Sjors

AU - de Rooij, Thijs

AU - Koerkamp, Bas Groot

AU - Shankar, Anuraj H.

AU - Siebert, Uwe

AU - Besselink, Marc G.

AU - Moser, A. James

N1 - Funding Information: Funding: This project was funded by non-profit partners: The Netherland-America-Foundation Fulbright Scholarship Program, the Alliance of Families Fighting Pancreatic Cancer, the Greg & Cathy Griffith Family Foundation, the John F. Fortney Foundation. Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved.

PY - 2021/12

Y1 - 2021/12

N2 - Objective: To quantify the nationwide impact of minimally invasive distal pancreatectomy (MIDP) on major morbidity as compared with open distal pancreatectomy (ODP).Background: A recent randomized controlled trial (RCT) demonstrated significant reduction in time to functional recovery after MIDP compared with ODP, but was not powered to assess potential risk reductions in major morbidity.Methods: International cohort study using the American College of Surgeons' National Quality Improvement Program (ACS-NSQIP) (88 centers; 2014-2016) to evaluate the association between surgical approach (MIDP vs ODP) and 30-day composite major morbidity (CMM; death or severe complications) with external model validation using Dutch Pancreatic Cancer Group data (17 centers; 2005-2016). Multivariable logistic regression assessed the impact of nationwide MIDP rates between 0% and 100% on postoperative CMM at conversion rates between 0% and 25%, using estimated marginal effects. A sensitivity analysis tested the impact at various scenarios and patient populations.Results: Of 2921 ACS-NSQIP patients, 1562 (53%) underwent MIDP with 18% conversion, and 1359 (47%) underwent ODP. MIDP was independently associated with reduced CMM [odds ratio (OR) 0.50, 95% confidence interval (CI) 0.42-0.60, P < 0.001], confirmed by external model validation (n = 637, P < 0.003). The association between rising MIDP implementation rates and falling postoperative morbidity was linear between 0% (all ODP) and 100% (all MIDP). The absolute risk reduction for CMM was 11% (95% CI 7.3%-15%) at observed conversion rates and improved to 14% (95% CI 11%-18%) as conversion approached 0%. Similar effects were seen across subgroups.Conclusion: This international study predicted a nationwide 11% risk reduction for CMM after MIDP versus ODP. which is likely to improve as conversion rates decrease. These findings confirm secondary outcomes of the recent LEOPARD RCT.

AB - Objective: To quantify the nationwide impact of minimally invasive distal pancreatectomy (MIDP) on major morbidity as compared with open distal pancreatectomy (ODP).Background: A recent randomized controlled trial (RCT) demonstrated significant reduction in time to functional recovery after MIDP compared with ODP, but was not powered to assess potential risk reductions in major morbidity.Methods: International cohort study using the American College of Surgeons' National Quality Improvement Program (ACS-NSQIP) (88 centers; 2014-2016) to evaluate the association between surgical approach (MIDP vs ODP) and 30-day composite major morbidity (CMM; death or severe complications) with external model validation using Dutch Pancreatic Cancer Group data (17 centers; 2005-2016). Multivariable logistic regression assessed the impact of nationwide MIDP rates between 0% and 100% on postoperative CMM at conversion rates between 0% and 25%, using estimated marginal effects. A sensitivity analysis tested the impact at various scenarios and patient populations.Results: Of 2921 ACS-NSQIP patients, 1562 (53%) underwent MIDP with 18% conversion, and 1359 (47%) underwent ODP. MIDP was independently associated with reduced CMM [odds ratio (OR) 0.50, 95% confidence interval (CI) 0.42-0.60, P < 0.001], confirmed by external model validation (n = 637, P < 0.003). The association between rising MIDP implementation rates and falling postoperative morbidity was linear between 0% (all ODP) and 100% (all MIDP). The absolute risk reduction for CMM was 11% (95% CI 7.3%-15%) at observed conversion rates and improved to 14% (95% CI 11%-18%) as conversion approached 0%. Similar effects were seen across subgroups.Conclusion: This international study predicted a nationwide 11% risk reduction for CMM after MIDP versus ODP. which is likely to improve as conversion rates decrease. These findings confirm secondary outcomes of the recent LEOPARD RCT.

UR - http://www.scopus.com/inward/record.url?scp=85121968394&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000003659

DO - 10.1097/SLA.0000000000003659

M3 - Article

C2 - 31756173

AN - SCOPUS:85121968394

SN - 0003-4932

VL - 274

SP - E966-E973

JO - Annals of Surgery

JF - Annals of Surgery

IS - 6

ER -

International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this